The effect of okra powder on blood sugar levels in pre-diabetic patients

Study of Okra( Abelmoschus esculentus ) Powder effects on Glucose Level, inflammatory factors ( IL-6?TNF-

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201026049154N1

Enrollment

Registered

2020-11-08

Start date

2020-11-21

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-diabetes.

Interventions

Intervention 1: Intervention group: 500 mg okra powder capsules, two capsules, three times a day, half an hour before meals, orally for at least 8 weeks for randomized patients in this group will be p

Eligibility

Sex/Gender

All

Age

30 Years to 55 Years

Inclusion criteria

Inclusion criteria: Fasting blood sugar between 100 and 125 mg per deciliter

Exclusion criteria

Exclusion criteria: Pregnancy and lactation in women Existence of mental disorders at the same time that make it difficult to cooperate Concomitant diseases such as heart disease, renal failure, thyroid disease, inflammatory diseases and allergies Taking non-steroidal anti-inflammatory drugs Taking steroid drugs

Design outcomes

Primary

Measure	Time frame
Reduce fasting blood sugar. Timepoint: At the beginning of the study and after 8 weeks of consumption of okra powder. Method of measurement: Blood sample analysis.	—

Secondary

Measure	Time frame
HbA1C. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Blood sample analysis.;Measurement of interleukin 6 (one of the inflammatory factors) in the blood. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Blood sample analysis.;Measurement of blood TNF-. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Blood sample analysis.;Evaluation of miR-15a expression (one of the diabetes-related miRs). Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: With Real-time pcr method.;Expression of miR-126 expression (one of the diabetes-related miRs). Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: With Real-time pcr method.	—

Measure

Time frame

HbA1C. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Blood sample analysis.;Measurement of interleukin 6 (one of the inflammatory factors) in the blood. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Blood sample analysis.;Measurement of blood TNF-. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Blood sample analysis.;Evaluation of miR-15a expression (one of the diabetes-related miRs). Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: With Real-time pcr method.;Expression of miR-126 expression (one of the diabetes-related miRs). Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: With Real-time pcr method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Afsharmanesh

Gorgan University of Medical Sciences

mra448@yahoo.com+98 916 616 2697

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026